BerGenBio reports second quarter and half year 2022 financial results and provides business update (1) , a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the second quarter and half year ended June 30, 2022 and provided a business update.
